AECOPDAECOPD BIOMASSNCT07509736
Effect of Pulmonary Rehabilitation in Females With Acute Exacerbation of COPD Induced by Biomass Fuel Smoke
A study testing Intervention 1 → Arm 1 (pulmonary rehabilitation group). in people with AECOPD and BIOMASS FUEL, run by Beni-Suef University.
Trial summary
COPD represents an important public health challenge that is both preventable and treatable. GOLD is committed to improving the health of people at risk of and with COPD, wherever they happen to have been born, and wishes to do its bit to help achieve the United Nations Sustainable Development Goal to reduce premature… Read more about this study
- Who is it for?
- Ages 50 years and older, women only
- Conditions the study is for
- AECOPD, BIOMASS FUEL, Pulmonary Rehabilitation
- What is being tested?
- Intervention 1 → Arm 1 (pulmonary rehabilitation group).
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 20 Mar 2026to 20 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Only females diagnosed with a history of using biomass fuel for cooking and heating during their lifetime with no history of smoking or being Ex smoker nor a non-smoker.
- Participants in clear consciousness.
- participants diagnosed with shortness of breath or dyspnea that was not caused by heart disease, pneumothorax, or pulmonary oedema
Who cannot join
- Systolic blood pressure lower than 90 mmHg.
- Participants with unstable psychological status, hemoptysis, pneumothorax, pulmonary edema.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Marwa Mohammed Mohammed Eleawa, Assistant professor contact
About this study
Official title: Effect of Pulmonary Rehabilitation in Females With Acute Exacerbation of COPD Induced by Biomass Fuel Smoke Randomized Controlled Trial
COPD represents an important public health challenge that is both preventable and treatable. GOLD is committed to improving the health of people at risk of and with COPD, wherever they happen to have been born, and wishes to do its bit to help achieve the United Nations Sustainable Development Goal to reduce premature mortality from non-communicable diseases - including COPD - by one third by 2030. GOLD aims in stable COPD to relieve symptoms, improve exercise tolerance and improve health status. Non-pharmacological interventions for those high-risk groups of patients, studies of intervention strategies both during inpatient stay and shortly after discharge have been undertaken, to decrease readmission rates and improve QOL, including disease-specific self-management, pulmonary rehabilitation, and early medical follow-up.Seeking for allow cost way to alleviate patients' symptoms in order to increase independence and QOL.
Read the detailed description
The study aimed to identify the effect of pulmonary rehabilitation on exercise tolerance, anxiety, depression, dyspnea and time to discharge from hospital in a group of COPD females admitted to inpatient wards till discharge from hospital.
- Conditions
- AECOPD, BIOMASS FUEL, Pulmonary Rehabilitation
- Being tested
- Intervention 1 → Arm 1 (pulmonary rehabilitation group).
- Keywords
- AECOPD-Anexity-depression-Biomass fuel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intervention 1 → Arm 1 (pulmonary rehabilitation group).Other
Arm1: pulmonary rehabilitation group participants will perform physical therapy program and receive standardized pulmonary rehabilitation.
Intervention(s): pulmonary rehabiliation program
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | Pulmonary rehabilitation group will receive In-patient interdisciplinary standardized pulmonary rehabilitation program plus the standarized medical treatment Receives: Other: Intervention 1 → Arm 1 (pulmonary rehabilitation group). |
| Arm 2 | Active comparator | Medical tratment group participants only receive medical treatment Receives: Other: Intervention 1 → Arm 1 (pulmonary rehabilitation group). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exercise tolerance
It measures functional capacity and exercise tolerance and it measured by 6 minutes walk test usually participants walk in 30 meters distance in the usual waling pace
Measured: 2 months (8 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2026
- Study start20 Mar 2026 (estimated)
- Primary completion10 Jun 2026 (estimated)
- Study completion20 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AECOPDStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Females in group A will receive In-patient interdisciplinary standardized pulmonary rehabilitation program included breathing exercises, bronchial hygiene, health education, low-load resistance exercise (15%-30% of 1 repetition maximum (1-RM) as tolerated), aerobic training in the form of walking exercise under supervision of physiotherapist with intensity of rate of perceived dyspnea (RPD) of 4-6 (10 points scale), duration of 20 minutes or as tolerated \[30\].While group B will b control group only receive medical treatment
- Masking
- Double blind
- Who is masked
- Care provider, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, MarwaM, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07509736
- Sponsor's protocol ID
- FPT-BSU rec
- Acronym
- AECOPD BIOMASS
- Status last verified
- Mar 2026
- First submitted
- 24 Mar 2026
- Last updated
- 3 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The study aimed to identify the effect of pulmonary rehabilitation on exercise tolerance, anxiety, depression, dyspnea, and time to discharge from hospital in a group of COPD females admitted to inpatient wards till discharge from hospital.
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Pulmonary Rehabilitation in Females With Acute Exacerbation of COPD Induced by Biomass Fuel Smoke Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07509736
- Acronym / sponsor ID
- AECOPD BIOMASS / FPT-BSU rec
- Conditions
- AECOPD, BIOMASS FUEL, Pulmonary Rehabilitation
- Keywords
- AECOPD-Anexity-depression-Biomass fuel
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 20 Mar 2026 (estimated)
- Primary completion
- 10 Jun 2026 (estimated)
- Study completion
- 20 Jun 2026 (estimated)
- First posted
- 3 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
COPD represents an important public health challenge that is both preventable and treatable. GOLD is committed to improving the health of people at risk of and with COPD, wherever they happen to have been born, and wishes to do its bit to help achieve the United Nations Sustainable Development Goal to reduce premature mortality from non-communicable diseases - including COPD - by one third by 2030. GOLD aims in stable COPD to relieve symptoms, improve exercise tolerance and improve health status. Non-pharmacological interventions for those high-risk groups of patients, studies of intervention strategies both during inpatient stay and shortly after discharge have been undertaken, to decrease readmission rates and improve QOL, including disease-specific self-management, pulmonary rehabilitation, and early medical follow-up.Seeking for allow cost way to alleviate patients' symptoms in order to increase independence and QOL.
Detailed description
The study aimed to identify the effect of pulmonary rehabilitation on exercise tolerance, anxiety, depression, dyspnea and time to discharge from hospital in a group of COPD females admitted to inpatient wards till discharge from hospital.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Females in group A will receive In-patient interdisciplinary standardized pulmonary rehabilitation program included breathing exercises, bronchial hygiene, health education, low-load resistance exercise (15%-30% of 1 repetition maximum (1-RM) as tolerated), aerobic training in the form of walking exercise under supervision of physiotherapist with intensity of rate of perceived dyspnea (RPD) of 4-6 (10 points scale), duration of 20 minutes or as tolerated [30].While group B will b control group only receive medical treatment
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Other: Intervention 1 → Arm 1 (pulmonary rehabilitation group).Pulmonary rehabilitation group will receive In-patient interdisciplinary standardized pulmonary rehabilitation program plus the standarized medical treatment |
| Arm 2 | Active comparator | Other: Intervention 1 → Arm 1 (pulmonary rehabilitation group).Medical tratment group participants only receive medical treatment |
Who may qualify
- Ages
- 50 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Only females diagnosed with a history of using biomass fuel for cooking and heating during their lifetime with no history of smoking or being Ex smoker nor a non-smoker.
- Participants in clear consciousness.
- participants diagnosed with shortness of breath or dyspnea that was not caused by heart disease, pneumothorax, or pulmonary oedema
Key exclusion criteria (2 listed)
- Systolic blood pressure lower than 90 mmHg.
- Participants with unstable psychological status, hemoptysis, pneumothorax, pulmonary edema.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intervention 1 → Arm 1 (pulmonary rehabilitation group).Arm1: pulmonary rehabilitation group participants will perform physical therapy program and receive standardized pulmonary rehabilitation. Intervention(s): pulmonary rehabiliation program | Other | Arm 1, Arm 2 |
Primary outcome
Exercise tolerance
Time frame: 2 months (8 weeks)
It measures functional capacity and exercise tolerance and it measured by 6 minutes walk test usually participants walk in 30 meters distance in the usual waling pace
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2026.
- Individual participant dataSharing planned: Yes. The study aimed to identify the effect of pulmonary rehabilitation on exercise tolerance, anxiety, depression, dyspnea, and time to discharge from hospital in a group of COPD females admitted to inpatient wards till discharge from hospital.
Related trials for AECOPD
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Not yet recruitingObservational study
The CANadian EXAcerbation of COPD Trial
COPD, AECOPD
Recruiting
COPD Flare-Up Clinic After Severe Exacerbations
COPD, COPD Exacerbation (AECOPD)
Active, not recruiting
Remote Monitoring of COPD Patients Experiencing an Acute Exacerbation Through Health Evaluations Using Wearable Mobile Technology
Chronic Obstructive Pulmonary Disease (COPD), Acute Exacerbation of COPD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marwa Mohammed Mohammed Eleawa, Assistant professor contact
Questions about this trial
What is this clinical trial studying?
A study testing Intervention 1 → Arm 1 (pulmonary rehabilitation group). in people with AECOPD and BIOMASS FUEL, run by Beni-Suef University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marwa Mohammed Mohammed Eleawa, Assistant professor (01000253865, dr.marwamohammed@pt.bsu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exercise tolerance (time frame: 2 months (8 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.